DARE – dare bioscience, inc. (US:NASDAQ)
Stock Stats
News
12/17
08:15 am
dare
Low
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
12/16
08:00 am
dare
Medium
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
12/10
08:00 am
dare
Medium
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
12/4
08:00 am
dare
Medium
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
11/15
08:03 am
dare
Medium
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/14/2024
04:01 pm
DARE
-10.0%
BEAT
8/13/2024
04:02 pm
DARE
-16.7%
BEAT
8/12/2024
04:10 pm
DARE
-1.6%
BEAT
5/14/2024
08:00 am
DARE
1.4%
MISS
12/17
08:15 am
Reiterates
Buy
Buy
HC Wainwright
Low
0.3%
11/15
08:03 am
Reiterates
Buy
Buy
HC Wainwright
Medium
-9.6%
10/24
08:08 am
Reiterates
Buy
Buy
HC Wainwright
Medium
-7.2%
12/16
08:05 am
dare
Low
Form 8-K Dare Bioscience, Inc. For: Dec 16
11/27
06:02 am
dare
Medium
Form EFFECT Dare Bioscience, Inc.
11/26
05:17 pm
dare
Medium
Form 424B3 Dare Bioscience, Inc.
11/22
05:01 pm
dare
Medium
Form D Dare Bioscience, Inc.
11/15
05:18 pm
dare
Low
Form S-1 Dare Bioscience, Inc.
Show more
Top News Gainers
2/21 Form SC 13D/A Dare Bioscience, Inc. Filed by: Dare Bioscience, Inc. 19.1%
1/15 Dare Bioscience Inc (NASDAQ: DARE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 15.1%
10/14 Daré Bioscience to Participate in Two Upcoming Investor Conferences 14.2%
2/6 Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates 13.9%
3/9 Form 3 Dare Bioscience, Inc. For: Mar 06 Filed by: Fair John A 9.8%
4/14 Form SEC STAFF LETTER Dare Bioscience, Inc. 6.4%
5/1 Form S-1 Dare Bioscience, Inc. 4.7%
3/16 Form 8-K Dare Bioscience, Inc. For: Mar 16 4.4%
11/14 Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update 4.2%
8/12 Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis 4.1%
Top News Decliners
11/21 Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform -16.7%
4/28 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $7.50 price target on the stock. -16.0%
1/30 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule -14.4%
11/12 Form 10-Q Dare Bioscience, Inc. For: Sep 30 -13.6%
5/8 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research -12.9%
12/18 Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study -12.7%
9/11 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Maxim Group. They set a "buy" rating and a $3.00 price target on the stock. -12.2%
1/23 Dare Bioscience Inc (NASDAQ: DARE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%
4/1 Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene® -10.5%
9/11 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics -10.0%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3